Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

LK Nielsen; C Stege; B Lissenberg-Witte; Ronnie van der Holt; UH Mellqvist; M Salomo; G Bos; MD Levin; Heleen Visser - Wisselaar; M Hansson; A van der Velden; W Deenik; J Coenen; M Hinge; S Klein; B Tanis; D Szatkowski; R Brouwer; M Westerman; R Leys; H Sinnige; E Haukas; K van der Hem; M Durian; P Gimsing; N van de Donk; Pieter Sonneveld; A Waage; N Abildgaard; S Zweegman

doi:10.3324/haematol.2019.222299

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

LK Nielsen, C Stege, B Lissenberg-Witte, Ronnie van der Holt, UH Mellqvist, M Salomo, G Bos, MD Levin, Heleen Visser - Wisselaar, M Hansson, A van der Velden, W Deenik, J Coenen, M Hinge, S Klein, B Tanis, D Szatkowski, R Brouwer, M Westerman, R LeysH Sinnige, E Haukas, K van der Hem, M Durian, P Gimsing, N van de Donk, Pieter Sonneveld, A Waage, N Abildgaard, S Zweegman

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

3 Downloads (Pure)

Original language	English
Pages (from-to)	1650-1659
Number of pages	10
Journal	Haematologica
Volume	105
Issue number	6
DOIs	https://doi.org/10.3324/haematol.2019.222299
Publication status	Published - 2020

Access to Document

10.3324/haematol.2019.222299

Repub_128539_O-A.pdfFinal published version, 2.38 MB

Cite this

Nielsen, LK., Stege, C., Lissenberg-Witte, B., van der Holt, R., Mellqvist, UH., Salomo, M., Bos, G., Levin, MD., Visser - Wisselaar, H., Hansson, M., van der Velden, A., Deenik, W., Coenen, J., Hinge, M., Klein, S., Tanis, B., Szatkowski, D., Brouwer, R., Westerman, M., ... Zweegman, S. (2020). Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica, 105(6), 1650-1659. https://doi.org/10.3324/haematol.2019.222299

@article{487e282ea3884da28d779c0797874d41,

title = "Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study",

author = "LK Nielsen and C Stege and B Lissenberg-Witte and {van der Holt}, Ronnie and UH Mellqvist and M Salomo and G Bos and MD Levin and {Visser - Wisselaar}, Heleen and M Hansson and {van der Velden}, A and W Deenik and J Coenen and M Hinge and S Klein and B Tanis and D Szatkowski and R Brouwer and M Westerman and R Leys and H Sinnige and E Haukas and {van der Hem}, K and M Durian and P Gimsing and {van de Donk}, N and Pieter Sonneveld and A Waage and N Abildgaard and S Zweegman",

year = "2020",

doi = "10.3324/haematol.2019.222299",

language = "English",

volume = "105",

pages = "1650--1659",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "6",

}

Nielsen, LK, Stege, C, Lissenberg-Witte, B, van der Holt, R, Mellqvist, UH, Salomo, M, Bos, G, Levin, MD, Visser - Wisselaar, H, Hansson, M, van der Velden, A, Deenik, W, Coenen, J, Hinge, M, Klein, S, Tanis, B, Szatkowski, D, Brouwer, R, Westerman, M, Leys, R, Sinnige, H, Haukas, E, van der Hem, K, Durian, M, Gimsing, P, van de Donk, N, Sonneveld, P, Waage, A, Abildgaard, N & Zweegman, S 2020, 'Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study', Haematologica, vol. 105, no. 6, pp. 1650-1659. https://doi.org/10.3324/haematol.2019.222299

In: Haematologica, Vol. 105, No. 6, 2020, p. 1650-1659.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

AU - Nielsen, LK

AU - Stege, C

AU - Lissenberg-Witte, B

AU - van der Holt, Ronnie

AU - Mellqvist, UH

AU - Salomo, M

AU - Bos, G

AU - Levin, MD

AU - Visser - Wisselaar, Heleen

AU - Hansson, M

AU - van der Velden, A

AU - Deenik, W

AU - Coenen, J

AU - Hinge, M

AU - Klein, S

AU - Tanis, B

AU - Szatkowski, D

AU - Brouwer, R

AU - Westerman, M

AU - Leys, R

AU - Sinnige, H

AU - Haukas, E

AU - van der Hem, K

AU - Durian, M

AU - Gimsing, P

AU - van de Donk, N

AU - Sonneveld, Pieter

AU - Waage, A

AU - Abildgaard, N

AU - Zweegman, S

PY - 2020

Y1 - 2020

U2 - 10.3324/haematol.2019.222299

DO - 10.3324/haematol.2019.222299

M3 - Article

SN - 0390-6078

VL - 105

SP - 1650

EP - 1659

JO - Haematologica

JF - Haematologica

IS - 6

ER -

Nielsen LK, Stege C, Lissenberg-Witte B, van der Holt R, Mellqvist UH, Salomo M et al. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica. 2020;105(6):1650-1659. doi: 10.3324/haematol.2019.222299